EGFR and cancer: EGFR-targeted therapies, such as cetuximab and panitumumab, may also affect neighboring stromal cells near the cancer cells, promoting an increase in the secretion of EGF, inducing resistance against EGFR-targeted therapies through continuous mitogen-activated protein kinase (MAPK) signaling [65].